Indeed, BAP1 is a tumor suppressor frequently inactivated in several cancers including MM and its depletion has been reported to decrease tumor cells sensitivity to Bor, raising the hypothesis that this proteasomal inhibitor may have an increased efficacy in MM patients whose tumors express the wild type BAP1 protein [81, 82]. Here, BAP1 is linked to Miyoshi myopathy.